Pharmacodynamic Study

Pharmacodynamic and pharmacokinetic interaction of *Panchagavya Ghrita* with phenytoin and carbamazepine in maximal electroshock induced seizures in rats

Rupa Joshi, K. H. Reeta, Surinder Kumar Sharma, Manjari Tripathi, Yogendra Kumar Gupta

Department of Pharmacology, All India Institute of Medical Sciences, 1Department of AYUSH, Ministry of Health and Family Welfare, Government of India, 2Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Abstract

**Introduction:** Traditionally, *Panchagavya Ghrita* (PG) has been used for the management of epilepsy, anxiety, fever and jaundice. It consists of five components of cow products namely, cow milk, clarified butter from cow milk, cow urine, curd from cow milk, and cow dung juice. **Aim:** To evaluate the effect of PG in maximal electroshock (MES) induced seizures model and its pharmacodynamic and pharmacokinetic interaction with phenytoin (PHT) and carbamazepine (CBZ) in rats. **Materials and Methods:** Male Wistar rats were administered PG 500, 1000, 2000, and 4000 mg/kg orally for 7 days and seizures were induced by MES. For interaction studies, PG (4000 mg/kg) was administered along with a sub-therapeutic dose of PHT (20 mg/kg, p.o.) and CBZ (10 mg/kg, p.o.). Behavioral parameters were assessed. Oxidative stress markers and serum levels of PHT and CBZ were estimated. **Results:** Tonic hind limb extension, cognitive impairment, and oxidative stress produced by MES were reversed by PG (4000 mg/kg). Co-administration of PG (4000 mg/kg) with a sub-therapeutic dose of PHT and CBZ potentiated antiepileptic effect and ameliorated cognitive impairment as well as oxidative stress. Although, there was a slight increase in serum levels of PHT and CBZ on co-administration with PG, it was statistically insignificant. **Conclusion:** Co-administration of PG with low doses of PHT and CBZ caused complete seizure protection. This suggests the potential of PG as an adjunct in epilepsy with improved efficacy and tolerability.

**Key words:** Carbamazepine, epilepsy, oxidative stress, *Panchagavya Ghrita*, phenytoin

Introduction

*Panchagavya Ghrita* (PG) is an Ayurvedic medicine consisting of five components, namely, cow milk, clarified butter from cow milk, cow urine, curd from cow milk, and cow dung juice. It has been recommended for treatment of *Apasmara* (epilepsy), *Jvara* (fever), and *Kamala* (jaundice) in Charaka Samhita. It is also known to have hepatoprotective and immunostimulant properties. Cow urine has been demonstrated to possess antioxidant property. Ayurveda mentions milk, ghee, and curd as good diet constituents. α-Lactalbumin (milk protein) is found to be effective in experimental models of seizure and epileptogenesis. PG alone as well as a constituent of many formulations has been shown to possess neuroprotective and anticonvulsant activities in rats. Antiepileptic drugs (AEDs) such as phenytoin (PHT), carbamazepine (CBZ), and sodium valproate are the mainstay of treatment in epilepsy and are associated with numerous side effects. Despite the availability of newer AEDs and alternative treatment options such as surgery, etc., the complete control of seizures is not seen in about 30% of the patients. Although monotherapy is the first line treatment option, polytherapy is widely practiced for refractory epilepsy with the hope of achieving full control of seizures. Side effects associated with monotherapy and polytherapy of AEDs are the major limitations.

Address for correspondence: Prof. Yogendra Kumar Gupta, Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029, India. E-mail: yk.ykgupta@gmail.com

For reprints contact: reprints@medknow.com

How to cite this article: Joshi R, Reeta KH, Sharma SK, Tripathi M, Gupta YK. Pharmacodynamic and pharmacokinetic interaction of *Panchagavya Ghrita* with phenytoin and carbamazepine in maximal electroshock induced seizures in rats. Ayu 2015;36:196-202.
Ayurvedic medicines with known anticonvulsant efficacy could be used as an adjuvant to conventional AEDs, to lower the doses as well as to reduce the side effects. Patients with epilepsy often concomitantly take the herbal medicines with modern AEDs without informing their physician. In previous studies, the interaction of herbal medicines with potential anticonvulsant activity has been evaluated with currently available AEDs with the intention to reduce the doses and side effects of AEDs. Considering the limitations of currently available AEDs and advantages of Ayurvedic medicines, the present study was planned to evaluate the anticonvulsant activity of PG and its protective effect against seizures associated cognitive impairment and oxidative stress in maximal electroshock (MES) induced seizures model in rats.

**Materials and Methods**

**Animals**
Experiments were performed in male Wistar rats weighing 200–250 g. The animals were obtained from the Central Animal Facility of All India Institute of Medical Sciences, New Delhi, India. The rats were maintained under standard laboratory conditions with natural dark and light cycle. They were allowed free access to standard dry rat diet (M/s Ashirwad Industry, Chandigarh, India) and tap water. Animals were aclimatised for 7 days prior to experimentation. However, the rats were deprived of food 12 h before the behavioral testing, as this is known to enhance their motivation to perform the test. The experimental protocols and procedures were reviewed and approved by the Institutional Animal Ethics Committee (no. 568/IAEC/2010).

**Materials**
PG was obtained from Arya Vaidya Sala, Kottakkal, Kerala, India (Batch no. 140563, date of manufacture - May 2011, date of expiry - May 2013, manufacturing licence no. 1/25D/76). Each 10 g constituted Ghrimat (cow ghee) - 10.549 ml; Gomaya Swaras (fresh cow dung - 10.549 ml; Gomutram (cow urine) - 10.549 ml; Dadhi (cow curd) - 10.549 ml; and Kshiram (cow milk) - 10.549 ml. PG was prepared and standardized as per the methods described in Ayurvedic Formulary of India (AFI). PG was melted by heating in a water bath (35–37°C) until it melts to a solution before administration to rats. The dose of PG was extrapolated from the human dose prescribed in AFI, which states 12 g daily. In different studies, PG has been used in a wide range of doses (500–4000 mg/kg) for experimental seizures as well as a hepatoprotective effect. In the present study, 500 mg/kg dose of PG was selected to evaluate its effect on MES induced seizures. Since, no protective effect was observed with this dose, higher doses were also used to study its dose-dependent effect. Sesame oil was used as a vehicle in vehicle control group.

PHT (Abbott, India) and CBZ (Novartis) were purchased from a local pharmacy. 5,5-Dithiobis (2-nitrobenzoic acid) (DTNB) and reduced glutathione (GSH) were purchased from Sigma Chemical Co., USA. All other reagents were of analytical grade and were obtained from Qualigens, India. PHT and CBZ were given in therapeutic and sub-therapeutic doses to evaluate any pharmacodynamic and pharmacokinetic interaction with PG. They were suspended in normal saline. Drugs/vehicles were given orally by gavage in a volume not >1 ml/100 g body weight. All the solutions were prepared afresh during experimentation.

**Experimental protocol**
Animals were randomly divided into twelve groups each containing six animals. Group I served as a normal control in which no active treatment was given. Group II was administered vehicle (sesame oil, 2 ml/kg) orally for 7 days. Groups III to VI were given PG orally in doses of 500, 1000, 2000, and 4000 mg/kg for 7 days, respectively. On day 7, seizures were induced by MES 120 min after last dose of PG/vehicle. For evaluation of pharmacodynamic interactions, therapeutic (40 mg/kg) and sub-therapeutic (20 mg/kg) doses of PHT were administered orally in a single dose on day 7 to groups VII and VIII. Group IX was given PG (4000 mg/kg) for 7 days and PHT (20 mg/kg) on day 7, MES was given 120 min after the last dose of PG and PHT. Groups X and XI received therapeutic (20 mg/kg) and sub-therapeutic (10 mg/kg) doses of CBZ orally on day 7. In group XII, PG (4000 mg/kg) was administered for 7 days and CBZ (10 mg/kg) orally on day 7. Seizures were induced by MES after 30 and 120 min administration of CBZ and PG, respectively.

**Measurement of lipid peroxidation**
Lipid peroxidation was measured through malondialdehyde (MDA) levels. Acetic acid 1.5 ml (20%) pH 3.5, 1.5 ml of
Estimation of glutathione
GSH was estimated by the method described by Ellman. To precipitate out the proteins, brain homogenate was centrifuged with 5% trichloro-acetic acid. The supernatant was separated; 2 ml of phosphate buffer (pH 8.4), 0.5 ml of Ellman’s reagent that is DTNB [5,5'-dithiobis-(2-nitrobenzoic acid)] and 0.4 ml of distilled water were added to 0.1 ml of this supernatant. After vortexing, the absorbance was read at 412 nm within 15 min in a spectrophotometer.

Pharmacokinetic study
The animals were randomly divided into eight groups (n = 6). The AEDs/PG was administered for 7 days. Group I was administered PHT (40 mg/kg, p.o), whereas group II received PHT (40 mg/kg, p.o) with PG (4000 mg/kg, p.o). Similarly, group III was administered PHT (20 mg/kg) and group IV was given PHT (20 mg/kg, p.o) along with PG (4000 mg/kg, p.o). Group V received CBZ (20 mg/kg, p.o) alone and group VI was administered CBZ (20 mg/kg, p.o) along with PG (4000 mg/kg, p.o). Group VII was given CBZ 10 mg/kg alone and group VIII was administered CBZ (10 mg/kg) along with PG (4000 mg/kg, p.o). The blood samples (1 ml) were collected from the retro-orbital plexus at Cmax (3 h for PHT and 1 h for CBZ) and 24 h after the last dose of PHT and CBZ administration. Serum levels of PHT and CBZ were estimated using high-performance liquid chromatography (HPLC).

Estimation of serum levels of phenytoin and carbamazepine using high-performance liquid chromatography
The collected blood was allowed to clot at room temperature for 30 min and was then centrifuged at 3000 rpm for 10 min. The serum was separated and stored in Eppendorf tubes at −80°C until further analysis. A standard curve in the concentration range of 1–100 µg/ml for PHT and CBZ was obtained. The levels of PHT and CBZ in rat serum were determined from the peak area – concentration ratio.

The analysis was performed by HPLC (Agilent 1200 series) using C-18 (250 mm × 4.6 mm) packed column as the stationary phase. The mobile phase containing 50 mM potassium di-hydrogen orthophosphate buffer, acetonitrile, and methanol in the ratio of 60:20:20 (v/v/v) was filtered through a 0.22 µm membrane filter (Millipore) and degassed prior to use. The flow rate was 1.2 ml/min. The detection was performed at the wavelength of 210 nm. Column oven temperature was maintained at 30°C. The sample injection volume was 10 µl.

Statistical analysis
The results are expressed as mean ± standard error of the mean. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Bonferroni post-hoc statistical tests for behavioral and oxidative stress data. The Chi-square test was used to compare the anticonvulsant effect between the groups. Unpaired t-test was used for serum levels of AEDs. All statistical analyses were performed using statistical package for social sciences (SPSS) v. 16 (Chicago, IL, USA). P < 0.05 was considered as significant.

Results

Effect on maximal electroshock induced seizures
Pretreatment with PG at the dose of 2000 and 4000 mg/kg showed 16.6% and 33.3% protection, respectively, against THLE induced by MES. The therapeutic doses of PHT (40 mg/kg) and CBZ (20 mg/kg) produced significant (P < 0.01) protection against MES induced THLE. However, no significant protection was observed at sub-therapeutic doses of PHT (20 mg/kg) and CBZ (10 mg/kg) against THLE as compared to MES group. Co-administration of PG (4000 mg/kg) with the lower doses of PHT (20 mg/kg) and CBZ (10 mg/kg) showed a significant (P < 0.05) increase in percentage protection against THLE in comparison to MES group [Table 1] indicating pharmacodynamic interaction between PG and PHT/CBZ.

Cognitive functions

Effect on elevated plus maze test
The initial transfer latency did not differ significantly, whereas there was a significant difference in retention transfer latency amongst the groups. Post-hoc analysis (F [11,60] = 16.398, P = 0.000) showed that retention transfer latency was significantly (P < 0.001) increased in the MES group as compared to normal control group, thus indicating impairment of memory in the MES group. A significant improvement in memory retention by PG was observed at the dose of 4000 mg/kg as indicated by decrease in retention transfer latency as compared to MES group which was comparable to that of the PHT treated group.

In case of pharmacodynamic study, the retention transfer latency was decreased significantly (P < 0.001) in PHT (40 mg/kg) and CBZ (20 mg/kg) groups as compared to the MES group. PHT and CBZ in the sub-therapeutic doses alone did not show

Table 1: Percentage protection against MES induced THLE in rats (n=6)

<table>
<thead>
<tr>
<th>Groups (n=6)</th>
<th>Percentage protection against tonic hind limb extension</th>
</tr>
</thead>
<tbody>
<tr>
<td>MES (70 mA, 0.2 s, 299 Hz)</td>
<td>0/6</td>
</tr>
<tr>
<td>PG 500 mg/kg</td>
<td>0/6</td>
</tr>
<tr>
<td>PG 1000 mg/kg</td>
<td>0/6</td>
</tr>
<tr>
<td>PG 2000 mg/kg</td>
<td>1/6 (16.6)</td>
</tr>
<tr>
<td>PG 4000 mg/kg</td>
<td>2/6 (33.3)</td>
</tr>
<tr>
<td>PHT 40 mg/kg</td>
<td>6/6 (100)**</td>
</tr>
<tr>
<td>PHT 20 mg/kg</td>
<td>3/6 (50)</td>
</tr>
<tr>
<td>PHT 20 mg/kg + PG 4000 mg/kg</td>
<td>4/6 (66.6)*</td>
</tr>
<tr>
<td>CBZ 20 mg/kg</td>
<td>6/6 (100)**</td>
</tr>
<tr>
<td>CBZ 10 mg/kg</td>
<td>3/6 (50)</td>
</tr>
<tr>
<td>CBZ 10 mg/kg + PG 4000 mg/kg</td>
<td>4/6 (66.6)*</td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.01, as compared to MES group; MES: Maximal electroshock, THLE: Tonic hind limb extension, PG: Panchagavya Ghrita, PHT: Phenytoin, CBZ: Carbamazepine
any significant improvement in retention transfer latencies ($P > 0.05$) whereas combination of PG (4000 mg/kg) with sub-therapeutic doses of PHT and CBZ showed a significant ($P < 0.001$) improvement in retention transfer latencies in comparison to the MES group [Figure 1].

**Effect on passive avoidance test**
ANOVA showed a significant difference between the retention transfer latency amongst the groups ($F [11,60] = 27.72, P = 0.000$). A significant decrease in retention latency ($P < 0.001$) in the MES group was observed as compared to normal control group whereas PG (4000 mg/kg) showed a significant ($P < 0.05$) increase in retention latency as compared to MES group. Similarly, retention latency was found to be increased significantly ($P < 0.001$) in the groups treated with PHT and CBZ at therapeutic doses. PHT at sub-therapeutic dose alone ($P < 0.05$) as well as in combination with PG (4000 mg/kg) showed a significant ($P < 0.01$) increase in retention latency as compared to the MES group. Moreover, CBZ at sub-therapeutic dose did not show a significant increase in retention latency whereas its co-administration with PG (4000 mg/kg) caused a significant ($P < 0.001$) increase in retention latency as compared to the group treated with PHT and CBZ at therapeutic doses. PHT at sub-therapeutic dose alone ($P < 0.05$) as well as in combination with PG (4000 mg/kg) also showed a significant increase in retention latency as compared to PG (4000 mg/kg) alone treated group ($P < 0.05$) and CBZ ($P < 0.01$) alone treated groups [Figure 2].

**Oxidative stress parameters**

**Effect on malondialdehyde levels in rat brain**
ANOVA showed a significant difference in MDA level in rat whole brain between the groups ($F [11,60] = 50.93, P = 0.000$). There was a significant increase ($P < 0.001$) in the MDA levels in MES group as compared to normal control group. There was a significant decrease ($P < 0.05$) in the MDA levels in the combination of sub-therapeutic doses of CBZ and PG (4000 mg/kg) as well as PG (4000 mg/kg) alone treated groups ($P < 0.01$) as compared to MES group ($P < 0.001$) as well as PG (4000 mg/kg) and CBZ alone treated groups ($P < 0.01$) [Figure 3].

**Effect on glutathione levels in whole rat brain**
A significant difference in GSH levels was observed amongst the groups ($F [11,60] = 15.71, P = 0.000$). There was a significant decrease ($P < 0.001$) in the GSH level in MES group in comparison to the normal control group. There was a significant improvement ($P < 0.05$) in the decreased levels of GSH in the PG (4000 mg/kg) treated group as compared to MES group. The therapeutic and sub-therapeutic doses of PHT and CBZ showed significantly ($P < 0.001$ and $P < 0.05$, respectively) reversal of the decreased GSH level in comparison to MES group. Moreover, concomitant administration of PG (4000 mg/kg) with sub-therapeutic doses of PHT and CBZ showed a significant increase in the GSH level in comparison to MES group ($P < 0.01$) [Figure 4].

**Effect on the serum levels of phenytoin and carbamazepine**
Though there was slight increase in the serum levels of both PHT and CBZ in groups co-administered with PG, the levels were however well within the therapeutic range in different groups and the difference was not statistically significant as compared to the groups administered these AEDs alone [Table 2].

**Discussion**

Although AEDs are the core of epilepsy treatment; however, approximately 30% of patients with epilepsy are still refractory to seizures. Therefore, there is a need for the development of...
AEDs with multiple mechanisms of action with no or minimal adverse effects. In the present study, the anticonvulsant effect of PG was investigated using MES induced seizure in rats. PG at the dose of 2000 and 4000 mg/kg exhibited 16.6% and 33.3% protection against THLE in MES induced seizures, respectively. This antiepileptic effect of PG is well documented in Ayurveda.

Since the combination of two or more AEDs is used to control refractory seizures, it is usually associated with more drug–drug interactions. Moreover, the side effects of the AEDs are reported to increase with an increase in dose. Concomitant use of alternative medicines and AEDs is very common in a patient due to lack of awareness of the interaction between these drugs. The consequences of interaction may be either lack of and/or diminished efficacy of AEDs as well as unexpected side effects. Therefore, concomitant use of herbal drugs with modern medicines created an urgent need to study herb-drug interactions. In the present study, co-administration of PG (4000 mg/kg) with sub-therapeutic doses of PHT and CBZ potentiated the percentage protection against THLE from 50% (sub-therapeutic dose of AEDs alone treated groups) to 66.6% (combination of AEDs and PG treated groups). Thus, PG increased the efficacy of PHT and CBZ.

PIIT and CBZ act through prolongation of Na+ channel inactivation. In a previous study, the anticonvulsant effect of PG was reported in the PTZ and MES seizure models in rats. Therefore, it can be hypothesized that GABA and voltage-gated channels are involved in the anticonvulsant activity of PG. This suggests that PG may act through both the mechanisms, thus, potentiating the antiepileptic effect of PHT and CBZ.

Cognitive impairment is an important consequence of epilepsy, and furthermore, the AED treatment often contributes to the worsening of cognitive functions such as memory, attention, and learning deficits. In concordance with the previous findings, results in the present study also showed MES-induced cognitive impairment. Memory function in this study was assessed by the passive avoidance test and the elevated plus maze test. An increase in retention transfer latency in elevated plus maze test and a decrease in retention latency in passive avoidance test was observed in MES treated rats as compared to the normal control indicating an impairment of memory function. The observed cognitive impairment in the MES group may be attributed to the either seizures itself or seizures associated free radical cascades. The therapeutic and sub-therapeutic doses of PIIT and CBZ significantly ameliorated the cognitive impairment in rats as compared to MES group but the improvement in cognitive function was less with sub-therapeutic doses of PIIT and CBZ treated groups. However, co-administration of PG (4000 mg/kg) along with sub-therapeutic doses of PIIT and CBZ caused significant reversal of cognitive impairment in rats as compared to MES as well as sub-therapeutic doses of PIIT and CBZ treated groups indicating potentiality of efficacy of PIIT and CBZ by PG.

Seizure activity and chronic AEDs treatment in epileptic patients have been associated with an increased level of free radicals and reduced activity of antioxidant defense mechanism(s) which may result into recurrent seizures and cognitive deficit.

Table 2: Effect of PG on serum levels (µg/ml) of PHT and CBZ

<table>
<thead>
<tr>
<th>Groups</th>
<th>Serum level (µg/ml)</th>
<th>3 h</th>
<th>24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHT 40 mg/kg</td>
<td>12.36±0.49</td>
<td>0.47±0.08</td>
<td></td>
</tr>
<tr>
<td>PHT 40 mg/kg + PG 4000 mg/kg</td>
<td>14.87±1.12</td>
<td>0.68±0.08</td>
<td></td>
</tr>
<tr>
<td>PHT 20 mg/kg</td>
<td>5.44±0.75</td>
<td>0.47±0.08</td>
<td></td>
</tr>
<tr>
<td>PHT 20 mg/kg + PG 4000 mg/kg</td>
<td>4.47±0.56</td>
<td>0.52±0.11</td>
<td></td>
</tr>
<tr>
<td>CBZ 20 mg/kg</td>
<td>4.37±0.36</td>
<td>0.56±0.12</td>
<td></td>
</tr>
<tr>
<td>CBZ 20 mg/kg + PG 4000 mg/kg</td>
<td>4.91±0.21</td>
<td>0.58±0.19</td>
<td></td>
</tr>
<tr>
<td>CBZ 10 mg/kg</td>
<td>1.76±0.16</td>
<td>0.09±0.03</td>
<td></td>
</tr>
<tr>
<td>CBZ 10 mg/kg + PG 4000 mg/kg</td>
<td>2.04±0.07</td>
<td>0.23±0.12</td>
<td></td>
</tr>
</tbody>
</table>

Data presented as mean±SEM (n=6), SEM: Standard error of mean, PG: Panchagavya Ghrita, PHT: Phenytoin, CBZ: Carbamazepine

Figure 3: Effect of Panchagavya Ghrita on whole-brain malondialdehyde levels in the maximal electroshock induced seizures in rats. Data represent mean ± standard error of mean (n = 6), *P < 0.05, **P < 0.01, ***P < 0.001, a - as compared to normal control group; b - as compared to maximal electroshock group, c - as compared to Panchagavya Ghrita 4000 mg/kg; d - as compared to phenytoin 20 mg/kg; e - as compared to carbamazepine 10 mg/kg; PHT: Phenytoin, CBZ: Carbamazepine

Figure 4: Effect of Panchagavya Ghrita on whole-brain glutathione levels in the maximal electroshock induced seizures. Data represent mean ± standard error of mean (n = 6), *P < 0.05, **P < 0.01, ***P < 0.001, a - as compared to normal control group; b - as compared to maximal electroshock group; c - as compared to Panchagavya Ghrita 4000 mg/kg; d - as compared to phenytoin 20 mg/kg; e - as compared to carbamazepine 10 mg/kg; PHT: Phenytoin, CBZ: Carbamazepine

Joshi, et al.: Panchagavya Ghrita in maximal electroshock induced seizures in rats
GSH is thought to play a central role in defense against reactive oxygen species. It can directly detoxify reactive oxygen species and can act as a substrate for several peroxidases.[13] The results of this study showing an increased oxidative stress in the seizure groups support the findings of the previous studies. In the present study, MES induced seizures caused an imbalance between oxidant and antioxidant system resulting oxidative stress as indicated by increased MDA levels and decreased GSH levels in MES group. The imbalance between antioxidant and oxidant defensive system may be responsible for seizures as well as impairment of memory function.[12] PHT and CBZ are the conventional AEDs found to be effective against MES induced seizures. Thus, the reduced GSH levels in MES group were reversed by treatment with therapeutic doses of PHT and CBZ by protecting the animals against MES induced seizures as well as an increase in oxidative stress.

In the present study, there was a decrease in the brain MDA and increase in the brain GSH levels in groups when PG was co-administered with sub-therapeutic doses of these AEDs. PG has been known to possess antioxidant activity revealed by in vitro assays.[13] Cow products especially cow urine is rich in volatile free acids, which is a very potent antioxidant agent in turn may be responsible for the protection against seizures and seizures associated deformities.[13,14]

PG produced an anticonvulsant action against MES induced seizures in rats and potentiated the antisiezure effect of PHT and CBZ in the MES model. However, co-administration of PG with PHT and CBZ produced a slight increase in their serum levels but the increase was statistically insignificant. This suggests the probable involvement of other mechanisms in the potentiation of the antiseizure effect of the sub-therapeutic doses of these AEDs by PG, which needs to be explored in further studies.

**Conclusion**

Panchagavya Ghrita at the dose of 4000 mg/kg showed an anticonvulsant effect against MES induced seizures and also potentiated the anticonvulsant effect of PHT and CBZ. Moreover, the alteration in the serum levels of PHT and CBZ, when co-administered with PG, was statistically insignificant. Therefore, PG can be a potential adjunct to the conventional AEDs as it helps in increasing the efficacy, reducing the dose and decreasing the side effects of these AEDs. Further studies can be planned to study mechanistic approaches to elucidate the antiepileptic activity of PG at different dose levels in different experimental models.

**Acknowledgment**

The authors are thankful to Council of Scientific and Industrial Research (CSIR), New Delhi, India, for providing financial assistance to carry out this research work.

**Financial support and sponsorship**

Council of Scientific and Industrial Research (CSIR), New Delhi, India, provided financial assistance (9/6 (431)/2011, EMR-I).

**Conflicts of interest**

There are no conflicts of interest.

**References**


